Figure 2.
Figure 2. Progression-free survival of newly diagnosed chronic myeloid leukemia patients treated with 400 mg imatinib daily according to Sokal risk at diagnosis.

Progression-free survival of newly diagnosed chronic myeloid leukemia patients treated with 400 mg imatinib daily according to Sokal risk at diagnosis.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal